Aviptadil: Class Effect of a Synthetic Vasoactive Intestinal Peptide as a Treatment Option in Patients with COVID-19 with Severe Respiratory Failure

Abstract

Despite dynamic drug and vaccine development processes to reduce the disease burden of COVID-19, the treatment options are still very limited. Vasoactive intestinal peptide (VIP) has a diversified physiological action with specific features of lung protection-related activities.

VIP inhibits severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) gene replication in human monocytes and the viral replication in Calu-3 cells, thus further reducing the generation of proinflammatory mediators. Aviptadil, a synthetic form of VIP, is the only pulmonary therapeutic agent to have been granted ‘fast track’ status by the U.S. Food and Drug Administration (FDA) and to be allowed into both Phase II and III clinical trials. Initial binding of Aviptadil with non-structural protein (nsp) 10 and nsp16, which may inhibit the 2'-O-methyltransferase activity of the SARS-CoV-2 nsp10 and nsp16 complex.

Aviptadil has already proved to be an effective option in the treatment of severe respiratory failures due to sepsis and other related lung injuries. Interim analysis results of this drug used in respiratory failure caused by SARS-CoV-2 has evolved a new hope in regard to safety and efficacy. The final results from a recently completed trial, as well as all currently ongoing trials, will clarify the class effect of this drug in the treatment of COVID-19 in future days.

INTRODUCTION

COVID-19 has created an unprecedented global situation over the last 18 months. As of 23rd November 2021, there have been 257,469,528 confirmed cases of COVID-19 reported to the World Health Organization (WHO), including 5,158,211 deaths worldwide. This pandemic has led to extensive research to evaluate the safety and efficacy of several repurposed but also some new drugs. Numerous clinical trials are ongoing to establish the clinical benefits of these drugs.
The mainstay of the treatment continues to be based on supportive care, with the possible use of pharmacological agents in patients with more severe illnesses. Antiviral agents such as remdesivir may help to shorten the duration of illness but may not be efficacious enough to provide the survival benefit in life-threatening situations. Hypoxic individuals, as well as those requiring supplemental oxygen and non-invasive or invasive ventilatory support, treated with low-dose steroids have shown improved survival outcomes, with robust data supporting the statistically significant clinical outcome parameters.

In an adjunct to that, parenteral as well as oral anticoagulants have shown promising results in regard to combatting fatal complications such as a pulmonary embolism in cases of moderate-to-severe illness, where individuals are hospitalised in dedicated isolation wards as well as intensive care settings. Convalescent plasma has not lived up to the promise it held as the recent randomised clinical trials failed to demonstrate any added benefit as far as the mortality and morbidities of the disease are concerned. Cytokine inhibitors such as tocilizumab and other immunomodulatory drugs need further evaluation among a larger participating population of clinical trials to establish their efficacy.

After performing an extensive literature review using three databases (PubMed, Scopus, and Cochrane), it has been found that, in spite of dynamic drug and vaccine development processes to reduce the disease burden of COVID-19, the disease may not be eradicated due to the evolution of newer mutant strains of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and logistical challenges in the administration of vaccines globally. Due to these reasons, the cornerstone of such disease management remains dependent, to a certain extent, on novel drug discoveries and their accelerated regulatory approval to be used on basis of investigational therapeutic tools.

Vasoactive intestinal peptide (VIP) was first isolated from a hog’s intestine by Said and Mutt in 1970. It is mainly located in the myenteric and sub-mucosal neurons as well as nerve terminals of the gastrointestinal tract and contains 28 residue amino acid peptides. Apart from the digestive system, it is widely distributed in both the peripheral and central nervous systems as well as the cardiovascular, respiratory, and reproductive systems. This gut peptide hormone belongs to the glucagon/secretin hormone superfamily and is produced by neuroendocrine cells, macrophages, and both B and T lymphocytes.

PHYSIOLOGY OF VASOACTIVE INTESTINAL PEPTIDES

VIP is highly expressed in the lung tissue (approximately 70%) and nasal mucosa. It exerts its action in the lung tissue via two types of receptors acting as G protein-couple receptors; VIP receptor Types 1 and 2 (VPAC1 and 2); and receptors that are also activated by the pituitary adenylate cyclase activating polypeptide, which belongs to the same family as VIP. The VPAC1 receptor is predominantly located in lung tissue and T lymphocytes whereas VPAC2 is found on smooth muscle, mast cell, and basal part of lung mucosa. VIP binds to alveolar Type II (AT-II) cells via the VPAC1 receptor. Despite comprising of only 5% of the total lung tissue, it plays an important role in surfactant production, which helps in the maintenance of alveolar Type I epithelial cells.

VIP augments surfactant production by upregulating the enzyme choline phosphate cytidylyl transferase, which induces the incorporation of methyl choline to phosphatidylcholine, a major component of pulmonary surfactant. Additionally, it induces the c-Fos protein expression in AT-II cells and upregulates surfactant protein A expression, both of which ultimately lead to surfactant production. It also inhibits apoptosis by blocking the activities of caspase, granzyme B, and perforin. It exerts non-adrenergic, non-cholinergic bronchodilatation, which is 100 times more potent than isoproterenol and 50 times more potent vasodilatation in both systemic and pulmonary arteries than prostacyclln. Preclinical experiments in mouse models have demonstrated their role in reducing ischaemia-induced reperfusion injuries.

Besides the impact on respiratory physiology, VIP also has several other significant actions such as:

- Positive chronotropic, ionotropic, and coronary vasodilatory actions
Secretion of water and electrolyte on gastrointestinal lumen, pancreatic juice, and bile
Stimulation of pepsinogen secretion
Regulation of Prolactin secretion and promoting vaginal lubrication
Inhibiting T lymphocyte proliferation
Promoting T-helper 2 lymphocytes differentiation against T-helper lymphocytes and regulatory T cell induction
Downregulating several macrophage-mediated inflammatory cytokines and proinflammatory receptors
Playing a role of an inhibitory neurotransmitter of the non-adrenergic, non-cholinergic autonomic nervous system
Inhibiting the synthesis as well as activation of nuclear factor κ-light-chain-enhancer of activated B cells, which block the process of TNF-α generation

RATIONALITY BEHIND OF USE OF VASOACTIVE INTESTINAL PEPTIDES IN COVID-19

Acute respiratory failure is a major cause of death due to the SARS-CoV-2 infection. It is attributed to a cytokine storm, preceded by the invasion of the alveolar cell by the virus itself and then rupture of that pulmonary epithelial cell. This invasion occurs once the virus enters the AT-II cell by binding its spike protein to the surface of the angiotensin-converting enzyme 2 receptors located on AT-II cells. AT-II cells express VPAC1 receptors on its surfaces, which the VIP binds to and prevents the process of apoptosis in lung injury. VIP inhibits SARS-CoV-2 gene replication in human monocytes and viral replication in Calu-3 cells, thus further reducing the generation of proinflammatory mediators that play a significant role in tissue injury in the course of the COVID-19 disease.

VIP has demonstrated its beneficial effects on lung injuries in several animal models (Table 1). Unlike the anti-IL-6 drugs, it preserves the surfactant production as well as protects the AT-II cells of the lung. Other than the surfactant producing and anti-inflammatory activity, VIP has the property of potentially inhibiting the Fas ligand expression and thereby halting the progression of Fas ligand-mediated cell death. Acute lung injury caused by the COVID-19 is also contributed to by the degranulation of serine proteases granzymes and the formation of perforin protein, which induces the rapid death of the target cells. As a proven inhibitor of granzyme and perforin, VIP plays an important role in the prevention of cell death in lung tissue.

AVIPTADIL USE IN CLINICAL PRACTICE

Aviptadil is a synthetic form of VIP, which is also known as RLF-100. It has been designated as an orphan drug by the U.S. Food and Drug Administration (FDA) to treat respiratory airway diseases such as asthma, chronic obstructive airway disease, cystic fibrosis, pulmonary hypertension, adult respiratory distress syndrome (ARDS), lung fibrosis, and sarcoidosis as well as in non-respiratory conditions such as erectile dysfunction.

It is available both intravenously and as inhalational preparations. The half-life of the drug is 1–2 min and the apparent volume of distribution is 14 mL/kg. This drug is almost eliminated by the renal route, where 35% elimination occurs in the first 4 hours and 90% occurs within 24 hours. It has no significant clinical drug–drug interactions and insufficient data is available on its use in pregnancy and lactation. Intravenous administration is associated with side effects like tachycardia, flushing, hypotension, diarrhoea, and alterations in ECG (bigeminy).

Patients with pulmonary arterial hypertension were successfully treated with inhaled aviptadil, which caused a reduction in pulmonary artery pressure and improved in cardiac output and mixed venous oxygen concentration. In another open label Phase II clinical study, 20 patients with histologically proven sarcoidosis were treated with inhaled aviptadil for 4 weeks, which caused a significant reduction of TNF-α and the increment of CD4+ CD127− CD25+ T cells in their bronchoalveolar lavage fluid.

A safety evaluation of aviptadil was performed by conducting five Phase II trials under the observation the European Medicines Agency (EMA) and aviptadil was found to be a well-tolerated drug, with fewer side effects such as hypotension, flushing, and diarrhoea. Another open label Phase I study was conducted in 2005...
with 8 patients suffering from sepsis-related ARDS (all were on mechanical ventilation), who had been treated with an intravenous aviptadil infusion over 12 hours (50–100 pmol/kg/hour). Seven among those eight critically ill patients were successfully taken off of the ventilator and discharged home. Other than that, no drug-related serious adverse events were recorded and serial estimation of the serum blood TNF-α level showed significant decrement at the end of the treatment.

ROLE PLAYED BY AVIPTADIL IN COVID-19

SARS-CoV-2 infection is characterised by a hyperimmune response and dysregulated productions of cytokines and chemokines, which play a pivotal role in severe lung injury and unfavourable clinical outcomes in patients with COVID-19.

Several non-structural proteins (nsp) play a significant role in SARS-CoV-2 viral RNA replication process. Among them, the SARS-CoV-2 nsp16–nsp10 complex works as a 2'-O-methyltransferase. This complex is also necessary to evade the immune recognition process. Results of in silico structural bioinformatics analyses have demonstrated the potential sites of binding specificity between aviptadil and nsp16. The interaction model also showed the process of the initial binding of aviptadil with nsp10 and nsp16, which may inhibit the 2'-O-methyltransferase activity of the SARS-CoV-2 nsp10/16 complex. The SARS-CoV-2 virus enters the AT-II cell through the binding of its spike protein to the angiotensin-converting enzyme 2 surface receptors.

Unlike the AT-I cells, only AT-II cells express the VPAC1 receptor that VIP binds to, thus VIP and its analogues deserve special attention as a therapeutic option to combat the hypoxemic lung injury in COVID-19.

Aviptadil is the only pulmonary therapeutic agent to have been granted ‘fast track’ status by the FDA and to be allowed into both Phase II and III clinical trials, as well as an expanded use protocol for those who are unable to enter the clinical trial due to excluded comorbidity.

The initial use of aviptadil via an intravenous route for the first time (after getting the authorisation of emergency use as an investigational new drug from the FDA) was reported in a case report by Jihad Georges Youssef et al. when a double lung transplant patient (additionally in a stage of antibody-mediated rejection) got infected with SARS-CoV-2 and subsequently developed severe respiratory failure and was treated with aviptadil at Houston Methodist Hospital, Texas, USA. After the third dose of aviptadil via infusion, there was a dramatic improvement in oxygen saturation and radiographic changes, which ultimately lead to the patient being discharged from the hospital and was alive until 28 days after post-discharge, as per the latest information gathered from the study.

In another case series, 21 consecutive lab-confirmed patients with SARS-CoV-2 and multiple comorbidities showed significant improvement both from the radiological as well as a clinical point of view after being treated with intravenous aviptadil. Most were sent back home after being weaned from mechanical ventilation and decannulated from extracorporeal membrane oxygenation support, which was also associated with biochemical improvements in the form of the steady decline of inflammatory markers (e.g., IL-6 and C-reactive protein).

Currently, nine clinical trials are on the list (two of which are in India), where aviptadil is being tried via both the inhalational and intravenous route and subsequently tested based on some outcome parameters to assess the safety and efficacy of the drug in comparison to the use of placebo, remdesivir, monoclonal antibodies, and other immunosuppressants in the treatment of COVID-19 that is complicated by severe respiratory failure. The details of those trials are summarised in Table 2. Among those nine trials, seven are in the recruitment stage, comprising the trial with maximum sample size, where one trial is completed and the data of the remaining one is available recently.

Of all the trials mentioned in Table 2, only one trial has been completed recently (in February 2021), which demonstrated promising results on the intravenous use of aviptadil in COVID-19. In this multicentre, placebo-controlled trial, 196 patients with COVID-19 respiratory failure were randomised 2:1 to receive 3 days of intravenous aviptadil or placebo. The primary endpoint was “alive and free from respiratory failure at
day 60.” The investigators also studied the mechanistic effect of aviptadil on blocking cytokine production and its link to survival and recovery from respiratory failure. It was found that, when controlling for baseline severity and site of care, patients treated with aviptadil were significantly more likely to be alive and free from respiratory failure at 60 days compared with those treated with placebo (p=0.02) and demonstrated significance on numerous other clinical endpoints. Without controlling for the site of care, a two-fold increased odds of survival was seen at 60 days (95% confidence interval: 1.0–3.9; p=0.035). Biomarker analysis demonstrates that aviptadil significantly decreased the probability of an IL-6 increase relative to placebo (50% versus 71%; p=0.04) and that preventing this cytokine rise was highly correlated with survival.

Table 1: Effect of vasoactive intestinal peptides on various experimental animal models of acute lung injury.

<table>
<thead>
<tr>
<th>Animal models tested for</th>
<th>Aetiopathology of lung injury</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>NDMD induced lung injury with arginine</td>
<td>Said (1996); Dickman et al. (2000)24</td>
</tr>
<tr>
<td>Guinea pig</td>
<td>Paraquat (methyl viologen)</td>
<td>Pakbaz et al. (1993)25</td>
</tr>
<tr>
<td>Rat</td>
<td>Hydrochloric acid induced pulmonary oedema</td>
<td>Foda (1988)26</td>
</tr>
<tr>
<td>Rat</td>
<td>Cobra venom factor model of septic shock</td>
<td>Mulligan (1992)27</td>
</tr>
</tbody>
</table>

NDMD: N-dimethyl daunomycin.

Table 2: Summary of current trials of aviptadil in COVID-19.

<table>
<thead>
<tr>
<th>Trial identifier</th>
<th>Drugs used</th>
<th>Location</th>
<th>Recruitment status</th>
<th>Estimated sample size</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT04844580</td>
<td>Aviptadil; placebo</td>
<td>Turkey</td>
<td>Recruiting</td>
<td>80</td>
</tr>
<tr>
<td>NCT04536350</td>
<td>Aviptadil; placebo</td>
<td>Switzerland</td>
<td>Recruiting</td>
<td>82</td>
</tr>
<tr>
<td>NCT04360096</td>
<td>Aviptadil; placebo</td>
<td>USA</td>
<td>Recruiting</td>
<td>144</td>
</tr>
<tr>
<td>NCT04843761</td>
<td>Aviptadil; remdesivir; placebo</td>
<td>USA</td>
<td>Recruiting</td>
<td>640</td>
</tr>
<tr>
<td>NCT04488081</td>
<td>Aviptadil; remdesivir; pulmozyme; celecoxib; famotidine; narsoplimab; cyclosporine; ICI4</td>
<td>USA</td>
<td>Recruiting</td>
<td>1,500</td>
</tr>
<tr>
<td>NCT04311697</td>
<td>Aviptadil; placebo</td>
<td>USA</td>
<td>Completed</td>
<td>196</td>
</tr>
<tr>
<td>NCT04453839</td>
<td>Aviptadil</td>
<td>USA</td>
<td>Available</td>
<td>196</td>
</tr>
<tr>
<td>CTRI/2021/04/033118</td>
<td>Aviptadil; placebo</td>
<td>India</td>
<td>Recruiting</td>
<td>150</td>
</tr>
<tr>
<td>CTRI/2021/06/034373</td>
<td>Aviptadil; placebo</td>
<td>India</td>
<td>Recruiting</td>
<td>152</td>
</tr>
</tbody>
</table>
and recovery (p<0.0001), regardless of baseline severity or treatment site.\textsuperscript{52}

As the study is limited by its insufficient power and other important outcome analysis as well as the 60-day endpoint assessment as reports are still awaited, it is too early to conclude the study objective of this trial. It is also true that, as per the available data about the use of this molecule in ARDS-related sepsis as well as its use in the preclinical lung injury model, this molecule retains the hope to become an effective treatment option in the management of respiratory failure caused by SARS-CoV-2 infection.

**CONCLUSION**

Aviptadil, as a synthetic VIP, holds a promising place in the armamentarium of treatment of SARS-CoV-2. The class effect of this drug is already established in the almost similar clinical scenario of ARDS caused by sepsis as well as other related lung injuries in preclinical models. The safety data of this molecule has also had a favourable notation on the use in several respiratory airway diseases. Current interim analysis data about the safety and efficacy of this molecule is encouraging in spite of limitations regarding the sample size of the study affecting the power. Upcoming results from the ongoing clinical trials will play a pivotal role in treatment policy-making aspects. More robust data on a larger target population will be immensely helpful to prove its impact on the reduction of the disease burden in the treatment of this deadly virus.

**References**


